propranolol / Generic mfg. - LARVOL DELTA

Beta Blocker Intoxications in Belgium: A Data Analysis with Focus on Propranolol. (PubMed, Pharmacy (Basel)) - " Propranolol shows a distinct toxicological profile and is disproportionately involved in intoxications, especially in vulnerable groups and in combination with psychoactive drugs. These findings highlight the need for greater awareness, targeted prevention, and careful monitoring."

Journal • Cardiovascular • Psychiatry

Interventions for Migraine and Sleep: A Systematic Review Exploring Their Bidirectional Association. (PubMed, Eur J Neurol) - "Integrated approaches combining migraine and sleep interventions show promise for symptom management. Further research is needed to refine treatment strategies and assess long-term effects."

Clinical • Journal • Review • CNS Disorders • Insomnia • Migraine • Pain • Sleep Disorder

Reconsolidation Blockade with Propranolol as a Novel Treatment for Chronic Low-Back Pain: A Double-Blind Randomized Placebo-Controlled Feasibility Study. (PubMed, J Pain Res) - "Preliminary results suggest no effect on pain symptoms. Additional studies are warranted to assess the adequacy of reactivation procedures (proper reactivation being required to trigger reconsolidation), and to investigate whether the absence of negative pain beliefs might be a prerequisite (unmet in this study) for the success of the intervention."

Clinical • Journal • Back Pain • CNS Disorders • Lumbar Back Pain • Mood Disorders • Musculoskeletal Pain • Pain • Post-traumatic Stress Disorder

The effect of medical therapies for subthreshold abdominal aortic aneurysm growth and mortality: a network meta-analysis of randomized controlled trials. (PubMed, Interdiscip Cardiovasc Thorac Surg) - "Current evidence highlights ongoing uncertainty regarding the efficacy of medical therapies in reducing subthreshold AAA growth rates, rates of referral for surgical repair, or overall mortality. The absence of statistically significant benefit may reflect underpowered datasets rather than definitive treatment inefficacy. Future large-scale, appropriately powered randomized controlled trials evaluating emerging medical treatments are required to accurately assess their clinical potential."

Journal • Retrospective data • Cardiovascular

Association of nonselective β blockers with the development of hepatocellular carcinoma in liver cirrhosis: a meta-analysis. (PubMed, Ann Hepatol) - "NSBBs may play a role in preventing the occurrence of HCC in liver cirrhosis patients. Future research should focus on risk stratification and monitoring protocols to advance personalized prevention."

Journal • Retrospective data • Fibrosis • Gastroenterology • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammatory Bowel Disease • Liver Cirrhosis • Oncology • Solid Tumor

Lacosamide Versus Propranolol in Episodic Migraine, a Randomized Controlled Double-blinded Trial. (PubMed, Mol Neurobiol) - P3 | "Lacosamide was well-tolerated by migraine patients. Trial registration: registered on clinicaltrial.gov, NCT05851781-30/04/2023."

Clinical • Journal • CNS Disorders • Epilepsy • Migraine • Pain

Propranolol enhances the oncolytic effect of newcastle disease virus on canine mammary tumor cell by modulating the IFN-I-mediated JAK-STAT signaling pathway. (PubMed, Vet Q) - "However, the combination markedly enhanced intratumoral NDV replication by inhibiting IFN-I production and the JAK-STAT signalling pathway. These findings indicate that propranolol enhances NDV-mediated oncolysis in CMT by inhibiting the IFN-I/JAK-STAT pathway, increasing viral load, and represents a promising combined therapeutic strategy."

Journal • Breast Cancer • Oncology • Solid Tumor

R-propranolol Promotes the Adipogenesis and Subsequent Apoptosis of Hemangioma Stem Cells through the PERK Signaling Pathway. (PubMed, Am J Pathol) - "This effect was attenuated by the PERK inhibitor GSK2606414. Immunostaining of clinical specimens further showed that PERK expression was higher in involuting IH samples than in proliferating IH samples. Together, these findings demonstrate that R-propranolol promotes adipogenesis and subsequent apoptosis of HemSCs through activation of the PERK signaling pathway."

Journal

Vitex Simplicifolia Abates Cadmium-Induced Cardiotoxicity Through Antioxidant Activity and Keap1 Targeting. (PubMed, Chem Biodivers) - "Group 2 received no treatment, whereas groups 3 and 4 were treated with 200 and 400 mg/kg VSME, respectively, and group 5 received 10 mg/kg propranolol (standard drug), all for 21 days via oral administration...These compounds exhibited superior drug-likeness, pharmacokinetics, and safety profiles compared to the standard Keap1 inhibitor, CPUY192018. These findings suggest that VSME may exert cardioprotective effects partly through antioxidant activity and potential interference with the Keap1-Nrf2 interaction, as supported by molecular docking."

Journal • Cardiovascular • Dyslipidemia • CAT • CRP • KEAP1

Loneliness, serotonin, and medial prefrontal cortex: some empirical and theoretical considerations. (PubMed, Pharmacol Biochem Behav) - No abstract available

Journal

Sirolimus Therapy in Generalized Lymphatic Anomaly With Tuberculosis: A Case Report. (PubMed, Pediatr Pulmonol) - "The patient showed limited response to propranolol and pleurodesis but improved after initiation of sirolimus and vincristine. The child subsequently demonstrated sustained clinical improvement with combined sirolimus and ATT. This case highlights the rare coexistence of GLA and tuberculosis, emphasizing the need to consider dual pathology when evaluating persistent pleural effusions in children."

Journal • Cough • Infectious Disease • Pain • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Characterizing the Impact of Dedicated Hemangioma New Patient Visit Slots on Infantile Hemangioma Evaluation and Treatment (AAD 2026) - "Mean age at presentation, propranolol initiation rates, age at treatment initiation, and frequency of high-risk IHs did not differ significantly between cohorts... HNPV slots did not significantly reduce age at presentation or treatment initiation overall. However, physicians were able to see higher risk patients at earlier ages outside of HNPV slots. This suggests factors affecting initial evaluation beyond simply access to care are deserving of further study."

Clinical

Therapeutic Response to Propranolol in Infantile Hemangiomas: A Retrospective Study in the Dominican Republic (AAD 2026) - "Propranolol is highly effective for treating infantile hemangiomas, especially the superficial subtype. Early initiation, ideally before six months of age, is associated with better outcomes. Recommendations include thorough cardiovascular screening, close monitoring during treatment, and effective family education and support."

Retrospective data • Cardiovascular

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies (clinicaltrials.gov) - P2 | N=67 | Not yet recruiting | Sponsor: Yonsei University

New P2 trial • Cardiovascular • CNS Disorders • Oncology

Real-world effectiveness of Carvedilol vs.Propranolol for primary prophylaxis of variceal bleeding and impact on endoscopic burden (EASL 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Cardiovascular • Fibrosis • Hepatology • Hypertension • Immunology • Portal Hypertension

An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma (ASH 2025) - P2 | "Mediantimes to neutrophil and platelet engraftment were 11 days (range 11-17 days) and 15 days (range 11-27days), respectively.ConclusionsBurixafor, in combination with propranolol and G-CSF, demonstrated an excellent safety profile andeffectively mobilized sufficient HPCs for AHCT, including patients previously treated with lenalidomideand daratumumab. Notably, burixafor enabled same-day administration with leukapheresis, offering akey advantage over other CXCR4 inhibitors, such as plerixafor and motixafortide through its rapidmobilization kinetics. Its favorable safety profile, characterized by minimal adverse events, supporting itspotential clinical utility."

Clinical • IO biomarker • P2 data • Cardiovascular • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hypotension • Multiple Myeloma • Musculoskeletal Diseases • Musculoskeletal Pain • CD34 • CXCR4

Comparison of Beta-Blocker to No Beta-Blocker in Patients With Traumatic Brain Injury (SCCM 2026) - "Additional subgroup analyses compared propranolol vs other BB, early vs late BB initiation, and mild and moderate vs severe TBI... Beta-blocker use was associated with reduced in-hospital mortality and observed in patients with severe TBI."

Clinical • CNS Disorders • Vascular Neurology

A Case of Iodinated Contrast-Induced Thyroid Storm and Respiratory Arrest (SCCM 2026) - "His agitated delirium persisted despite maximum recommended dose of dexmedetomidine and repeated doses of haloperidol, ultimately resolving only after intubation and administration of IV propofol. History revealed noncompliance with methimazole and a previous history of TS...He was treated with IV hydrocortisone, propranolol, and propylthiouracil, with subsequent clinical improvement. Older adults with hyperthyroidism often present to the ED and the growing reliance on iodinated contrast raises concerns for contrast-induced thyrotoxicosis. In individuals with thyroid disease, iodide exposure can trigger clinically significant thyrotoxicosis. Therefore, it is crucial to assess risk factors such as history of thyroid disease/thyroid storm and remain vigilant for signs of thyrotoxicosis following contrast administration, particularly when a patient exhibits an atypical clinical course."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Endocrine Disorders • Grave’s Disease • Immunology • Infectious Disease • Metabolic Disorders • Movement Disorders • Pulmonary Embolism • Respiratory Diseases • TG

The Paralysis That Wouldn't Quit: A Hyperthyroid Crisis Resistant to Methimazole (SCCM 2026) - "Methimazole is first-line, but resistance—though rare—can hinder treatment, requiring alternatives like Propylthiouracil or definitive therapy with iodine ablation or thyroidectomy. We report a case of recurrent TPP in a young male with suspected methimazole resistance and persistent thyrotoxicosis.Description: A 22-year-old male with known history of Grave's Disease previously only on propranolol was admitted to the intensive care for thyroid storm with severe muscle weakness attributed to severe hypokalemia (1.6 mmol/L). The patient was treated with rapid potassium replacement and started on beta blockers, methimazole and hydrocortisone and eventually discharged...Definitive therapy with surgery or iodine ablation should always be recommended in these cases. Prompt recognition of possible methimazole resistance is key to avoid recurrent thyrotoxicosis, including hypokalemic period paralysis."

Endocrine Disorders • Grave’s Disease • Immunology • Musculoskeletal Pain

Early Propranolol Administration Improves Outcomes in Traumatic Brain Injury: A Scoping Review (SCCM 2026) - "There is a critical gap in the acute care for patients with traumatic brain injury. A small body of evidence suggests that early propranolol administration significantly benefits TBI patients and reduces their burden on the healthcare system. Future research will determine the proper utilization of propranolol and its implications across age, sex, and other relevant risk factors."

Review • Cardiovascular • CNS Disorders • Hypertension • Vascular Neurology

Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma (clinicaltrials.gov) - P2/3 | N=40 | Recruiting | Sponsor: West China Hospital | Not yet recruiting ➔ Recruiting

Enrollment open

HERBAL REMEDY, SHOCKING OUTCOME: QTC-PROLONGING SUPPLEMENT IN A PATIENT WITH CONGENITAL LONG QT SYNDROME (ACC 2026) - "She was discharged on propranolol with her ICD reset to 60 bpm without recurrent arrhythmia. Berberine use should be avoided in patients with LQTS given its documented QT-prolonging effects. This case underscores the importance of thorough medication counseling in at-risk populations, especially for supplements lacking robust safety data."

Clinical • Cardiovascular • Ventricular Tachycardia • KCNH2

IT'S A NEW DAWN, IT'S A NEW DELTA WAVE - RECALCITRANT NEONATAL SVT CEASES WITH THE MANIFESTATION OF PREEXCITATION (ACC 2026) - "Therapy with amiodarone, flecainide, and propranolol finally achieved sinus rhythm with frequent AP echoes...The child remains SVT free on sotalol, propranolol and digoxin while weaning amiodarone at 1 year... Multidrug SVT therapy may create complex interactions."

Cardiovascular • Ventricular Tachycardia

COMBINED PRE- AND POST-CAPILLARY PULMONARY HYPERTENSION IN THYROTOXICOSIS: INVASIVE HEMODYNAMIC INSIGHTS. (ACC 2026) - "She was started on methimazole, propranolol and steroids for severe thyrotoxicosis. Our case highlights rare documented hemodynamic profile of thyrotoxicosis with severe RHF. Pathophysiology of thyrotoxicosis associated with PH remains unclear and needs further studies."

Cardiovascular • Congestive Heart Failure • Grave’s Disease • Heart Failure • Hepatology • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

RACING HORMONES, FAILING HEART: A CASE OF THYROTOXICOSIS-INDUCED HEART FAILURE WITH REDUCED EJECTION FRACTION (ACC 2026) - "Decision-Making: The patient was treated with propranolol, methimazole, furosemide, sacubitril-valsartan, and dapagliflozin. Early recognition of thyrotoxic cardiomyopathy is crucial, as it represents a reversible cause of HFrEF. Management requires a multidisciplinary approach focused on restoring a euthyroid state and addressing acute cardiac complications. Delayed diagnosis or suboptimal treatment increases the risk of cardiovascular morbidity and mortality."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Endocrine Disorders • Grave’s Disease • Heart Failure • Pulmonary Disease